Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP1 | P13497 | 20/20 | 0.65 |
| ▸ | MMP3 | P08254 | 3/20 | 0.65 |
| ▸ | MMP2 | P08253 | 6/20 | 0.58 |
| ▸ | PDE4A | P27815 | 1/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.55 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.55 |
| ▸ | MMP1 | P03956 | 1/20 | 0.52 |
| ▸ | MMP13 | P45452 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6178438 | 0.90 | BMP1 (0.81) | BMP1MMP3MMP2PDE4APDE4B | |
| SCHEMBL27586683 | 0.89 | BMP1 (0.80) | BMP1MMP3MMP2PDE4APDE4B | |
| SCHEMBL6428493 | 0.89 | BMP1 (0.80) | BMP1MMP3MMP2PDE4APDE4B | |
| SCHEMBL6782493 | 0.88 | BMP1 (0.60) | BMP1MMP3MMP2PDE4APDE4B | |
| SCHEMBL6428270 | 0.85 | BMP1 (0.65) | BMP1MMP3MMP2PDE4APDE4B | |
| SCHEMBL6428304 | 0.84 | BMP1 (0.64) | BMP1MMP3MMP2PDE4APDE4B | |
| SCHEMBL5406857 | 0.83 | BMP1 (0.81) | BMP1MMP3MMP1MMP13 | |
| SCHEMBL6782498 | 0.82 | BMP1 (0.50) | BMP1MMP3MMP2PDE4APDE4B | |
| SCHEMBL6428451 | 0.82 | BMP1 (0.64) | BMP1MMP3MMP2PDE4APDE4B | |
| SCHEMBL6429139 | 0.81 | BMP1 (0.84) | BMP1MMP3MMP2PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1373231-B1 | 3-HETEROCYCLYL-PROPANO-HYDROXAMIC ACID AS PCP INHIBITORS | PFIZER LTD (GB) | 2005-06-08 | — | — | EP | disclosed |
| US-6831088-B2 | Wound healing agents; antiscarring agents | PFIZER INC. | 2004-12-14 | — | — | US | disclosed |
| US-20040058917-A1 | 3-Heterocyclylpropanohydroxamic acid PCP inhibitors | FISH PAUL VINCENT (GB) | 2004-03-25 | — | — | US | disclosed |
| EP-1373231-A1 | 3-HETEROCYCLYLPROPANOHYDROXAMIC ACID PCP INHIBITORS | Pfizer Limited (GB) | 2004-01-02 | — | — | EP | disclosed |
| US-6645993-B2 | 3-heterocyclylpropanohydroxamic acid PCP inhibitors | WARNER-LAMBERT COMPANY | 2003-11-11 | — | — | US | disclosed |
| US-20020187979-A1 | 3-heterocyclylpropanohydroxamic acid PCP inhibitors | FISH PAUL VINCENT (GB) | 2002-12-12 | — | — | US | disclosed |
| WO-2002079175-A1 | 3-HETEROCYCLYLPROPANOHYDROXAMIC ACID PCP INHIBITORS | PFIZER LIMITED (GB) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058917-A1 | 3-Heterocyclylpropanohydroxamic acid PCP inhibitors | PAH, FAP, PREP | BMP1 77/4885MMP3 38/4885MMP2 34/4885 |
| US-20020187979-A1 | 3-heterocyclylpropanohydroxamic acid PCP inhibitors | MMP1, CPA1, PAH | BMP1 26/4885MMP3 32/4885MMP2 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.